Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
SIRT-IN-2
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "SIRT-IN-2" in MCE Product Catalog:
Cat. No.: HY-16616
CAS No.: 1431411-66-3
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC50s of 4, 4, 7 nM, respectively.
1
1 Cited Publications
Cat. No.: HY-16615
CAS No.: 1431411-60-7
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 nM, respectively.
Cat. No.: HY-155727
CAS No.: 670267-73-9
Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC50s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines .
Cat. No.: HY-146013
CAS No.: 2402779-21-7
Target:
Research Areas:
Sirt1/2-IN-1 (Compound 7) is a SIRT1 and SIRT2 inhibitor with IC50 values of 1.81, 2.10 and 20.5 µg/mL against SIRT1, SIRT2 and SIRT3, respectively. Sirt1/2-IN-1 displays activity in hyperacetylation of α-tubulin protein with an IC50 of 32.05 µg/mL. Sirt1/2-IN-1 shows prominent anticancer activity .
Cat. No.: HY-155728
CAS No.: 301313-42-8
Sirt1/2-IN-3 (compound PS9) is a dual inhibitor of SIRT1/2 with IC50s of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respsectivley. Sirt1/2-IN-3 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-3 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines .
Cat. No.: HY-155729
CAS No.: 2999646-13-6
Sirt1/2-IN-4 (compound PS3) is a triple inhibitor of SIRT1/2/3 with IC50s of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respsectivley. Sirt1/2-IN-4 completely blocks p53 deacetylation, with potential anti-cancer activity .
Cat. No.: HY-W109401
CAS No.: 1431411-18-5
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with IC50 values of >50 μM. SIRT-IN-6 is promising for research of metabolic, inflammatory, oncologic and neurodegenerative disorders .
Cat. No.: HY-114906
CAS No.: 388086-13-3
SIRT1/2/3-IN-2 (compound 9) is a potent SIRT inhibitor, with inhibition rates of 27%, 72%, and 71% targeting SIRT1, SIRT2, and SIRT3, respectively, at 200 μM. SIRT3 is a potential tumor suppressor or promoter, and its increased transcription may be associated with lymph node-positive breast cancer and oral squamous cell carcinoma .
Cat. No.: HY-136713
CAS No.: 143034-06-4
Target:
Research Areas:
Sirt1/2-IN-5 is a SIRT1/SIRT2 inhibitor with human SIRT1 IC50 0.3 μM and human SIRT2 IC50 values 1.2 μM and pIC50 5.82. Sirt1/2-IN-5 inhibits NAD +-dependent deacetylase activity of SIRT1 and SIRT2. Sirt1/2-IN-5 can be used for the research of cancer, neurodegenerative disease [2].
Cat. No.: HY-153509
CAS No.: 1392810-44-4
Sirtuin-IN-1 (Compound 18) is a SIRT1/2 inhibitor (IC50s: 6.2 μM and 4.2μM for SIRT1 and SIRT2, respectively). Sirtuin-IN-1 induces G1 cell cycle arrest. Sirtuin-IN-1 exhibits potent anti-cancer activity against glioma .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
